​

Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LGND Stock Forecast

Ligand Pharmaceuticals (LGND) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $340.20, with a high of $358.00 and a low of $326.00. This represents a 13.35% increase from the last price of $300.14.

$50 $120 $190 $260 $330 $400 High: $358 Avg: $340.2 Low: $326 Last Closed Price: $300.14

LGND Stock Rating

Ligand Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (72.22%), 4 Hold (22.22%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 4 13 Strong Sell Sell Hold Buy Strong Buy

LGND Price Target Upside V Benchmarks

TypeNameUpside
StockLigand Pharmaceuticals13.35%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5517
Avg Price Target$340.20$340.20$269.47
Last Closing Price$300.14$300.14$300.14
Upside/Downside13.35%13.35%-10.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 2627---9
Jul, 2627---9
Jun, 2627---9
May, 2627---9
Apr, 2627---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 06, 2026Joseph PantginisH.C. Wainwright$358.00$313.5514.18%19.28%
Aug 03, 2026Leland GershellOppenheimer$326.00$287.5413.38%8.62%
Jul 20, 2026Matt HewittCraig-Hallum$345.00$303.0313.85%14.95%
Jul 15, 2026RBC Capital$340.00$300.9712.97%13.28%
Jul 08, 2026Annabel SamimyStifel Nicolaus$332.00$319.433.94%10.62%
Apr 30, 2026Joseph PantginisH.C. Wainwright$289.00$224.8628.52%-3.71%
Apr 28, 2026RBC Capital$252.00$241.794.22%-16.04%
Apr 27, 2026Stifel Nicolaus$255.00$241.795.46%-15.04%
Apr 14, 2026Joseph PantginisH.C. Wainwright$243.00$231.115.14%-19.04%
Feb 24, 2026Joseph PantginisH.C. Wainwright$239.00$190.8625.22%-20.37%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 06, 2026H.C. WainwrightBuyBuyhold
Aug 03, 2026OppenheimerOutperformOutperformhold
Jul 20, 2026Craig-HallumBuyBuyhold
Jul 16, 2026BenchmarkBuyBuyhold
Jul 15, 2026RBC CapitalOutperformOutperformhold
Jul 09, 2026Bank of America SecuritiesBuyBuyhold
Apr 28, 2026RBC CapitalOutperformOutperformhold
Apr 15, 2026CitigroupBuyBuyhold
Apr 14, 2026H.C. WainwrightBuyBuyhold
Mar 24, 2026CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.46$-1.98$3.02$-0.22$6.44---
Avg Forecast$3.87$2.79$5.35$5.66$6.07$6.78$7.72$8.54
High Forecast$4.25$2.85$5.47$6.80$7.57$7.17$7.90$8.74
Low Forecast$3.59$2.64$4.97$3.47$4.97$6.40$7.17$7.93
Surprise %-10.59%-170.97%-43.55%-103.89%6.10%---

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$241.54M$196.25M$131.31M$167.13M$268.09M---
Avg Forecast$269.76M$203.95M$128.89M$163.37M$187.13M$225.03M$262.60M$302.00M
High Forecast$290.66M$207.04M$129.19M$163.82M$187.65M$226.62M$263.92M$307.38M
Low Forecast$255.22M$195.53M$128.58M$162.49M$186.43M$223.45M$261.28M$285.48M
Surprise %-10.46%-3.78%1.88%2.31%43.26%---

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.14M$-33.36M$52.15M$-4.03M$124.45M---
Avg Forecast$51.75M$26.46M$53.82M$91.14M$111.34M$120.52M$133.80M$151.64M
High Forecast$63.33M$40.01M$85.52M$120.75M$134.42M$127.40M$140.26M$155.16M
Low Forecast$40.17M$12.92M$22.12M$61.53M$88.26M$113.64M$127.34M$140.86M
Surprise %10.42%-226.06%-3.09%-104.42%11.78%---

LGND Forecast FAQ

Is Ligand Pharmaceuticals stock a buy?

Ligand Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ligand Pharmaceuticals is a favorable investment for most analysts.

What is Ligand Pharmaceuticals's price target?

Ligand Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $340.2 over the next 12 months. The price target range spans from $326 at the low end to $358 at the high end, suggesting a potential 13.35% change from the previous closing price of $300.14.

How does Ligand Pharmaceuticals stock forecast compare to its benchmarks?

Ligand Pharmaceuticals's stock forecast shows a 13.35% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ligand Pharmaceuticals over the past three months?

  • August 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ligand Pharmaceuticals’s EPS forecast?

Ligand Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $6.78, marking a 5.28% increase from the reported $6.44 in 2025. Estimates for the following years are $7.72 in 2027, and $8.54 in 2028.

What is Ligand Pharmaceuticals’s revenue forecast?

Ligand Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $225.03M, reflecting a -16.06% decrease from the reported $268.09M in 2025. The forecast for 2027 is $262.6M, and $302M for 2028.

What is Ligand Pharmaceuticals’s net income forecast?

Ligand Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $120.52M, representing a -3.16% decrease from the reported $124.45M in 2025. Projections indicate $133.8M in 2027, and $151.64M in 2028.